China yesterday defended its decision to overturn Pfizer's patent for Viagra in a ruling seen as a setback to protection of intellectual property rights in the country.
The US makers of the top selling erectile disfunction drug were in breach of China's intellectual property rights (IPR) law when they failed to accurately explain "technological" uses of Viagra's key ingredient, an official with the State Intellectual Property Office (SIPO) said.
"If you widen the description of the [ingredient's] technological uses, you could likely be violating the patent right of others," the SIPO official said on condition of anonymity.
PHOTO: AFP
Although the same office granted Pfizer in 2001 a patent for sildenafil citrate, Viagra's key active ingredient, the official maintained SIPO had the right to revoke the patent.
A Pfizer company statement promised to appeal the judgement.
The official said after approval of sildenafil citrate, more than 10 Chinese companies filed official complaints, forcing the SIPO to review its decision.
"When there are [domestic] requests to invalidate the patent, our review committee should go back to look to it," she said.
"We did grant the patent to Pfizer before, but that does not mean that we are really giving it to you," she said.
She further argued that given the potential size of the Chinese market the office could not afford to be imprudent.
"We are very cautious when we grant a patent, because a patent means a market, and that can mean allowing the monopolization of a market," she said.
The ruling has heightened concerns in the US and is likely to do so in the EU, as they have watched the case closely, concerned about intellectual property rights.
The US-China Business Council, a major Washington-based business association and lobby group, censured the decision and said it was "deeply concerned."
"Given how China has to strengthen IPR enforcement under its WTO obligations, its disheartening to see a lower-level agency make a decision clearly responding to pressure from Chinese companies," said the council's director, Patrick Powers.
Powers added the New York-based Pfizer, the world's largest pharmaceutical company, would take legal action in China, where foreign companies find their products are routinely copied and counterfeits are widespread.
China's decision likely does not augur well for the pharmaceutical industry, which has viewed the case as a litmus test for the protection of intellectual property rights.
"If China is going to embark on a strategy of patent nullification in order to avoid paying research and development costs, that does not bode well for a strong commitment to strengthening IPR," Powers said.
Pfizer plans to introduce up to 15 new medicines in China in the next five years to treat conditions such as neurological and cardiovascular problems, reports said.
"Intellectual property protection is essential to these plans," the company said.
Pfizer added that it "was extremely disheartened" by the move in China, where it had invested US$500 million by bringing advanced medicines, building facilities and hiring and training local employees.
A Viagra pill costs about one yuan (US$0.10) to make but Pfizer sells them in China for 98 yuan a tablet.
The entry of local producers is likely to see the price drop to 22 yuan a pill, the price of lookalike domestic products which do not contain Viagra's key ingredient.
DEATH THREAT: A MAC official said that it has urged Beijing to avoid creating barriers that would impede exchanges across the Strait, but it continues to do so People should avoid unnecessary travel to China after Beijing issued 22 guidelines allowing its courts to try in absentia and sentence to death “Taiwan independence separatists,” the Mainland Affairs Council (MAC) said yesterday as it raised its travel alert for China, including Hong Kong and Macau, to “orange.” The guidelines published last week “severely threaten the personal safety of Taiwanese traveling to China, Hong Kong and Macau,” MAC Deputy Minister and spokesman Liang Wen-chieh (梁文傑) told a news conference in Taipei. “Following a comprehensive assessment, the government considers it necessary to elevate the travel alert to orange from yellow,” Liang said. Beijing has
Chinese President Xi Jinping (習近平) yesterday said that the Chinese Communist Party was planning and implementing “major” reforms, ahead of a political conclave that is expected to put economic recovery high on the agenda. Chinese policymakers have struggled to reignite growth since late 2022, when restrictions put in place due to the COVID-19 pandemic were lifted. The world’s second-largest economy is beset by a debt crisis in the property sector, persistently low consumption and high unemployment among young people. Policymakers “are planning and implementing major measures to further deepen reform in a comprehensive manner,” Xi said in a speech at the Great Hall
CIVIL DEFENSE: More reservists in alternative service would help establish a sound civil defense system for use in wartime and during natural disasters, Kuma Academy’s CEO said While a total of 120,000 reservists are expected to be called up for alternative reserve drills this year, compared with the 6,505 drilled last year, the number has been revised to 58,000 due to a postponed training date, Deputy Minster of the Interior Ma Shih-yuan (馬士元) said. In principle, the ministry still aims to call up 120,000 reservists for alternative reserve drills next year, he said, but the actual number would not be decided later until after this year’s evaluation. The increase follows a Legislative Yuan request that the Ministry of the Interior address low recruitment rates, which it made while reviewing
DETERRENCE: Along with US$500 million in military aid and up to US$2 billion in loans and loan guarantees, the bill would allocate US$400 million to countering PRC influence The US House of Representatives on Friday approved an appropriations bill for fiscal year 2025 that includes US$500 million in military aid for Taiwan. The legislation, which authorizes funding for the US Department of State, US foreign operations and related programs for next year, passed 212-200 in the Republican-led House. The bill stipulates that the US would provide no less than US$500 million in foreign military financing for Taiwan to enhance deterrence across the Taiwan Strait, and offer Taipei up to US$2 billion in loans and loan guarantees for the same purpose. The funding would be made available under the US’ Foreign Military